Would A Mortality Endpoint Be The Death Knell For Antibiotics Development?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Anti-Infective Drugs Advisory Committee meets Dec. 9 to discuss trial designs for community-acquired pneumonia, but a leading expert sees that as a step backward.